Taken together, our results demonstrate that, the combination of DSeA and TRAIL could be a novel strategy to overcome TRAIL resistance in malignant melanoma, and DSeA may be candidates for further evaluation as a chemosensitizer in clinical trails. Here, TNFSF10 is linked to melanoma.